10Mo·

Editas Medicine: CRISPR technology with great potential


  • Editas Medicine has entered into a license agreement with Vertex Pharmaceuticals for the development of CRISPR/Cas9-based therapies for Duchenne muscular dystrophy.
  • Editas Medicine has a strong pipeline portfolio with several promising candidates in clinical development.
  • Conclusion: Editas Medicine is a good buy for investors interested in the future of CRISPR technology.
27.12
Editas Medicine logo
Acheté à 9,685 €
5
Participez à la conversation